Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | TACR2 | P21452 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SHBG | P04278 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20874475 | 0.93 | RARB (0.56) | CA2CA1ALDH1A1HSD17B10HPGD | |
| SCHEMBL8081798 | 0.93 | ESR1 (0.59) | CA2ALDH1A1HSD17B10ESR1ADRA2A | |
| SCHEMBL8496560 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL177117 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL9579598 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL4810276 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL9154487 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL9253594 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL8702332 | 0.91 | ESR1 (0.63) | ALDH1A1HSD17B10ESR1ADRA2AADORA3 | |
| SCHEMBL10986143 | 0.87 | RARB (0.58) | ALDH1A1HSD17B10HPGDESR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2024-08-15 | — | — | US | disclosed |
| EP-4277897-A1 | FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| CN-115246834-B | Aldrisin derivative, preparation thereof and application thereof in preventing and treating plant viruses, killing insects and killing bacteria | 南开大学 | 2023-10-13 | — | — | CN | disclosed |
| CN-116710442-A | Compounds, compositions and methods for treating disorders | 成都安泰康赛生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-115246834-A | Aldisin derivative, preparation thereof and application thereof in preventing and treating plant viruses, killing insects and killing bacteria | 南开大学 | 2022-10-28 | — | — | CN | disclosed |
| WO-2022152097-A1 | FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2022-07-21 | — | — | WO | disclosed |
| US-9957213-B2 | Organic compound, liquid crystal composition, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO. (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9957213-B2 | Organic compound, liquid crystal composition, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO. (JP) | 2018-05-01 | — | — | US | disclosed |
| CN-102781884-B | Process for producing alpha-olefin oligomer | MITSUBISHI CHEMICAL CORP. (JP) | 2015-11-25 | — | — | CN | disclosed |
| CN-104926589-A | Process for producing alpha-olefin oligomer | MITSUBISHI CHEM CORP | 2015-09-23 | — | — | CN | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5877339-A | Process for preparing methyl dithiocarbazinate by reacting methyl bromide with the reaction product of carbon disulfide and hydrazine in an aqueous medium | BAYER CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5861526-A | Process for reducing dithiocarbazinate buildup in the preparation of methyl dithiocarbazinate | BAYER CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| EP-0866793-A4 | — | — | 1998-10-07 | — | — | EP | disclosed |
| EP-0866793-A1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1998-09-30 | — | — | EP | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0841325-A2 | A process for preparing methyl dithiocarbazinate by reacting methyl bromide with the reaction product of carbon disulfide and hydrazine in an aqueous medium | Bayer Corporation (US) | 1998-05-13 | — | — | EP | disclosed |
| EP-0841324-A2 | A proces for preparing methyl dithiocarbazinate by reacting methyl bromide with the reaction product of carbon disulfide, hydrazine and an adjunct base | Bayer Corporation (US) | 1998-05-13 | — | — | EP | disclosed |
| US-5668127-A | MYCOBACTERIUM TUBERCULOSIS, CLOSTRIDIUM | PATHOGENESIS CORPORATION (US) | 1997-09-16 | — | — | US | disclosed |
| WO-1997001562-A1 | NITROIMIDAZOLE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1997-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | CA2 2447/4885CA1 1979/4885ALDH1A1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.